Stock Market Research
Data-driven research from Equibles — every figure computed straight from SEC filings and market data, written up so the numbers tell you something.
Intel: The $465.7B market cap attached to a $57.0B money-losing business has one quarter to prove the Q2 2026 reset
Intel's 326.7% rally has priced in a turnaround the Q2 2026 print only just began to earn, with $57.0B of TTM revenue against -$77.0M of TTM EBIT. The Q3 2026 guide of $15.8B–$16.8B revenue and $0.31 GAAP EPS is the first datapoint that will decide whether the 41.8% non-GAAP gross margin holds and a dividend reinstatement becomes credible, or whether the -28.9% drawdown from $140.94 deepens.
AMD at 171.1× earnings is the cycle's most multiple-expanding bet, and Q2 2026 is the bar
Advanced Micro Devices trades at 171.1× on +34.3% revenue growth against Nvidia at 31.7× on +125.9% and Broadcom at 63.6× on +143% AI semiconductor growth, with the $11.2B Q2 2026 guide and initial Helios volume in Q3 now the only thing standing between the multiple holding and a re-rating toward Broadcom's 63.6×.
Micron's FQ4-26 guide of $50.0B and 86% gross margin: a single quarter larger than every full year through FY2024, with SK hynix's P&T7 build as the contestable mirror
Micron's FQ4-26 guided band exceeds every full fiscal year through FY2024 on a revenue base that has reset free cash flow to $18.3B in Q3 2026 and operating cash flow to $25.39B; the bull case rests on DRAM/NAND pricing, HBM4E absorption, and SCA lock-in holding ahead of SK hynix's Cheongju P&T7 advanced-packaging acceleration funded by a US$26.5B ADR allotment.
SoFi's 47.2% drawdown prices a credit-cycle casualty the Q1 2026 print disproves
Record originations across every lending product, 1,055,000 net new members, and a 22 basis-point NIM expansion to 5.94% sit beneath a 37.8x P/E and 14.7% short interest that price SoFi Technologies as if the bear case on capital deployment has already landed.
Hims & Hers has 26.4% shorts arguing against $2.9B of guided 2026 revenue; the Q2 print decides whether subscriber growth or ARPU decay wins
Hims & Hers closed at $32.84, off 50.4% from its 52-week high, with short interest at 26.4% of shares outstanding and the steepest positioning in the comp set against a +59.0% TTM revenue base and a 10%–12% full-year adjusted EBITDA guide — the next quarter decides whether the multiple re-rates with subscriber growth or compresses further on the 6% ARPU slide.
Rocket Lab: Backlog is converting, but the $39B market cap is paying for a Neutron debut the company has yet to validate
Rocket Lab enters Q2 2026 with record backlog of $2,219.8M and guided revenue of $225.0M–$240.0M, yet the stock trades at -55.2% from its $150.23 high on a $39.0B market cap against $679.6M of trailing revenue — a gap the equity-funded growth model and the un-flown Neutron debut have to close.
Emergent BioSolutions: leveraged biodefense name trades like a Narcan story while international MCM mix hits 37%
A $413.3M small-cap MCM franchise that has signed a $140M Canada agreement, a $54M ASPR award, and an ACAM2000 modification while net leverage fell to 1.9x and a $50M buyback was reauthorized — yet the equity is the worst YTD performer in the peer set with 19.9% short interest, leaving the print of the next four quarters to test whether the international MCM pivot can offset the Narcan generics drag.
Alexandria Real Estate Equities: stress event priced in, dividend reset is the test
Alexandria Real Estate Equities sits at a -38.8% trailing-twelve-month change and a -45.0% drawdown from its 52-week high after cutting its dividend from $1.32 to $0.72 and reporting zero public biotech leasing for the first quarter in company history. The peer office REIT cohort is reporting tightening markets and raising FFO midpoints, leaving ARE's stress specific to its public-biotech exposure — the setup turns on whether the 1.1 million square feet of leased vacant space delivers in September 2026, the $2.2 billion disposition program closes on pace, and public biotech leasing returns in Q2.